Navigation Links
A search for protection against chemotherapy cardiotoxicity
Date:12/20/2007

Researchers at the University of Grenoble, in France, have discovered that erythropoietin administration prevents acute cardiotoxic effects induced by doxorubicin and trastuzumab exposures. The research article describing this work entitled Erythropoietin pretreatment protects against acute chemotherapy toxicity in isolated rat hearts will be featured in the January 2008 issue of Experimental Biology and Medicine. Although rare, cardiotoxicity is a serious complication of cancer treatment. Indeed, the use of chemotherapeutic agents such as anthracycline or trastuzumab in oncology is limited by their cardiac toxicity. Therefore, it is of interest to identify new protective agents preventing these adverse effects.

The increasing use of doxorubicin and trastuzumab in adjuvant breast cancer therapy and the growing population of long-term pediatric cancer survivors mean that, more than ever, cardiotoxicity will continue to remain an important issue for oncology. Cardiomyopathy induced by chronic chemotherapy may result, at least in part, from acute cardiotoxic effects accompanying each drug exposure. said Professor Mireille Mousseau, head of the Department of Oncology.

The research team, led by Christophe Ribuot, a professor of pharmacology, explored the beneficial cardioprotective effect afforded by recombinant human erythropoietin (rhEPO) against various stresses, through experimental and clinical investigations.

This study is an excellent illustration of a fruitful collaboration between researchers in experimental pharmacology, Christophe Ribuot and Marie Joyeux-Faure, and the oncologist M. Mousseau. Here, we observed for the first time that only a unique rhEPO administration prevents cardiac damage induced by an acute doxorubicin or trastuzumab exposure, using the isolated rat heart model. said the articles first author Amandine Ramond. RhEPO administration could, therefore, be used during chemotherapy administration to reduce acute cardiotoxic effe
'/>"/>

Contact: Dr. Marie Faure
marie.faure@ujf-grenoble.fr
01-133-476-637-475
Society for Experimental Biology and Medicine
Source:Eurekalert

Page: 1 2

Related biology news :

1. Research shows skeleton to be endocrine organ
2. Newly created cancer stem cells could aid breast cancer research
3. Dominant cholesterol-metabolism ideas challenged by new research
4. Researchers identify proteins involved in new neurodegenerative syndrome
5. Texas researchers and educators head for Antarctica
6. MGH researchers describe new way to identify, evolve novel enzymes
7. University of Pennsylvania researchers develop formula to gauge risk of disease clusters
8. University of Oregon researcher finds that on waters surface, nitric acid is not so tough
9. U of MN researchers discover noninvasive diagnostic tool for brain diseases
10. U of Minnesota researchers discover noninvasive diagnostic tool for brain diseases
11. Story ideas from the Journal of Lipid Research

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2009)...ers, red deer have been caught in the hunters, sig... more than decorative. They are lethal weapons tha... from The University of York, UK, has been intrigu...alf a century and has become fascinated by the mec...ng collaboration with Tomas Landete-Castillejos at...
(Date:11/26/2009)...phylococcus Aureus ) and other drug-resistant bact...asma prototype devices have been developed to offe...ktails. , Two prototype devices have been develo...n (e.g. hands and feet) in hospitals and public sp...another to shoot bacteria-killing agents into infe...
(Date:11/25/2009)... Cell Death Research Laboratory in the University ... the prestigious Johnson & Johnson Focused Funding...in cell damage in Parkinson,s disease. The award, ...t of innovation and excellence in science, was ann...his month at an event at the Hyatt Regency Hotel i...
Breaking Biology News(10 mins):Tough yet stiff deer antler is materials scientist's dream 2Plasma produces KO cocktail for MRSA 2Plasma produces KO cocktail for MRSA 3Johnson & Johnson award goes to research of the cause of brain cell damage in Parkinson's 2New Media Led Effort Responds to AIDS Crisis in Black America 50086 1New Media Led Effort Responds to AIDS Crisis in Black America 50086 2New Media Led Effort Responds to AIDS Crisis in Black America 50086 3New Media Led Effort Responds to AIDS Crisis in Black America 50086 4New Media Led Effort Responds to AIDS Crisis in Black America 50086 5New Media Led Effort Responds to AIDS Crisis in Black America 50086 6Abused Kids Face Higher Cancer Risk 50083 1Abused Kids Face Higher Cancer Risk 50083 2U M study finds voice box can be preserved even with the largest cancers 50080 1U M study finds voice box can be preserved even with the largest cancers 50080 2
...gy infrastructure for researching and developing n...e industry hundreds of millions of dollars annuall... the National Institute of Standards and Technolog...T, the studys authors found that over the last two...ted from small-molecule chemicals to large-molecul...
...archers contributed to a national effort to sequen...hat will help advance research in a broad range of... to understanding a variety of human diseases. , ...ectionately as Chlamy, has long fascinated scienti...s that retains characteristics of both. Like green...
...greatly improves the ability to separate global wa...e gas is prepared for use, according to engineers ...yzed the new plastics performance. , Like a spong...astic permits carbon dioxide or other small molecu...t, while impeding natural gas (methane) movement t...
Other Biology News:Biopharmaceutical infrastructure key to lower drug development costs 2'Chlamy' genome holds clues for renewable energy, the environment and human health 2New membrane strips carbon dioxide from natural gas faster and better 2New membrane strips carbon dioxide from natural gas faster and better 3
(Date:11/30/2009)...RK, Nov. 30 The Michael... today announced $1.5 million in total awards to s...isease-modifying therapies for Parkinson,s disease...hes to Drug Discovery for Parkinson,s Disease pro...on, plc (NYSE: ELN ), a neuroscience-based biote...
(Date:11/30/2009)...STERDAM, November 30 Biopharmaceut...e first patients have been enrolled in its,multina...The study is,designed to show reduction in transpl...ng an allogeneic stem cell transplantation with a ... patients eligible for an allogeneic,stem cell tra...
(Date:11/30/2009)...LLE, Md., Nov. 30 Novava...mpleted enrollment in the Phase II clinical study ...ommended strains) VLP vaccine candidate in healthy...This randomized, double-blind, active-controlled s...unogenicity of two different doses (15 mcg and 60 ...
(Date:11/30/2009)...EATTLE, Nov. 30 Cell The...nced today that its new class of platinum-based an...rated a stronger anti-tumor potency and activity c...ounds as well as the ability to overcome cisplatin...e presented in a paper titled "Novel Bis-platinum ...
Breaking Biology Technology:The Michael J. Fox Foundation Announces $1.5 Million in Funding to Advance Development of Drug Targets for Disease-Modifying Parkinson's Disease Treatments 2The Michael J. Fox Foundation Announces $1.5 Million in Funding to Advance Development of Drug Targets for Disease-Modifying Parkinson's Disease Treatments 3Kiadis Pharma Announces Enrollment of First Patients in a Multinational Registration Study for ATIR(TM) 2NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults 2NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults 3NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults 4New Class of Platinum-Based Anti-Tumor Drugs, Bisplatinates, Demonstrates Potent Anti-Tumor Activity and Ability to Overcome Resistance to Currently Available Platinum-Based Agents 2New Class of Platinum-Based Anti-Tumor Drugs, Bisplatinates, Demonstrates Potent Anti-Tumor Activity and Ability to Overcome Resistance to Currently Available Platinum-Based Agents 3
...ED FOR TUESDAY, OCTOBER 28, SAN DIEGO, Oct. 22 N...ced today that the Company will report its third,q...ket closes on Tuesday,October 28, 2008. Neurocrine...iscuss its financial results and provide a Company...0 p.m. Eastern Time (2:00 p.m. Pacific,Time)., Pa...
...Inc.,(Nasdaq: TELK ) announced that its 2008 thir... on Wednesday, November 5, 2008 at 4:30 p.m. Easte...ease earlier that day of the,company,s financial r...008., The conference call will be accessible via ...lephone at 800-398-9367 or 612-332-7517. An,archiv...
...r Systems, Inc., a,medical device company developi... announced today that it has signed an agreement w...ercialize StemCor,s proprietary System,for the har...com/cgi-bin/prnh/20071030/STEMCORSYSTEMSLOGO ), S...spira will manage,the clinical trial program, lead...
Other Biology Technology:Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2008 Financial Results 2StemCor Signs Agreement With Hospira to Market New Medical Device to Oncologists and Hematologists 2StemCor Signs Agreement With Hospira to Market New Medical Device to Oncologists and Hematologists 3
Goat Anti-Human SCP3 / SYCP3 Affinity Purified Polyclonal Antibody, Unconjugated from R&D Systems
Rabbit Anti-Human ADH5 Polyclonal Antibody, Unconjugated from Proteintech Group, Inc.
Mouse Anti-Human Rad1 Monoclonal Antibody, Unconjugated, Clone 33 from R&D Systems
Cytological Nuclear Counterstain Kit - DAPI/SYTOX Green/PI - 300 slides from Molecular Probes (Invitrogen)
Biology Products: